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Abstract
Background: Angiogenesis is regarded as a hallmark in cancer development, and anti-angiogenic treatment is presently
used in non-small cell lung cancer (NSCLC) patients. MicroRNAs (miRs) are small non-coding, endogenous, single stranded
RNAs that regulate gene expression. In this study we aimed to identify significantly altered miRs related to angiogenesis in
NSCLC.
Methods: From a large cohort of 335 NSCLC patients, paraffin-embedded samples from 10 patients with a short disease
specific survival (DSS), 10 with a long DSS and 10 normal controls were analyzed. The miRs were quantified by microarray
hybridization and selected miRs were validated by real-time qPCR. The impacts of different pathways, including
angiogenesis, were evaluated by Gene Set Enrichment Analysis (GSEA) derived from Protein ANalysis THrough Evolutionary
Relationship (PANTHER). One of the most interesting candidate markers, miR-155, was validated by in situ hybridization (ISH)
in the total cohort (n=335) and correlation analyses with several well-known angiogenic markers were done.
Results: 128 miRs were significantly up- or down-regulated; normal versus long DSS (n=68) and/or normal versus short DSS
(n=63) and/or long versus short DSS (n=37). The pathway analysis indicates angiogenesis-related miRs to be involved in
NSCLC. There were strong significant correlations between the array hybridization and qPCR validation data. The
significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210
and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002),
though most prominent in the subgroup with nodal metastasis (r=0.34, P,0.001).
Conclusions: Several angiogenesis-related miRs are significantly altered in NSCLC. Further studies to understand their
biological functions and explore their clinical relevance are warranted.
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Introduction
Lung cancer is the number one cause of cancer related mortality
in both men and women, and approximately 80% are non-small
cell lung cancer (NSCLC) [1]. Despite emerging improvements in
early diagnosis and treatment modalities, the overall 5-year
survival is at meager 15%. TNM (Tumor, Nodes, Metastasis)
stage has been regarded the most important prognostic variable as
early stage disease is a prerequisite for complete surgical resection
necessary for potential cure. Treatment responses and side effects
from new treatment options have been closely related to different
histological entities of NSCLC [2–4]. However, targeted therapies
directed against specific cellular alterations require a precise sub-
classification of NSCLC which is largely beyond today’s staging
and routine diagnostic histopathological techniques [5].
MicroRNAs (miRs) are small non-coding, endogenous, single
stranded RNAs that regulate gene expression [6–9]. By regulating
the gene expression at a posttranscriptional level, miRs have a
large impact on a wide variety of pathways, including different
pathways related to cancer development. Several studies have
explored the deregulation of different miRs in NSCLC and their
potential oncogenic and tumor suppressor functions as well as their
prognostic impact [10–20].
Some miRs appear to be involved in angiogenesis [21–24].
Angiogenesis is a process of new blood vessel formation from
pre-existing ones, and plays a key role in tumor development
[25]. Angiogenic inhibitors are used in NSCLC treatment. The
monoclonal antibody bevacizumab in combination with
chemotherapy is FDA approved as a treatment option in
metastatic non-squamous NSCLC patients, and many tyrosine
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[3,26].
The first evidence showing miRs in the regulation of
angiogenesis came from Dicer knockout mice. Dicer is a critical
enzyme in miR synthesis. The Dicer-deficit mice died early during
development due to the thinning of vascular walls and severe
disorganization of the network of blood vessels [27]. Besides,
another murine study showed that a subset of miRs altered during
the angiogenic switch became oppositely regulated in response to
anti-angiogenic treatment [23].
In a large unselected NSCLC cohort we have previously studied
the prognostic impact of several key angiogenic growth factors and
receptors as well as the prognostic role of miR-155 and miR-126
by in situ hybridization [28–38]. Herein, we evaluated the miR
expression profiles in NSCLC by using tissue from selected
patients from this cohort. We aimed to identify interesting
angiogenesis-related miR candidates for further potential large-
scale and in-depth studies.
Results
Patients
Demographic, clinical, and histopathological variables in the
patient groups (long DSS, short DSS and controls) are shown in
Table 1. The median DSS were 8.0 (range 6.5–9.9) months and
160.5 (range 60.5–184.3) months in the low and high DSS group,
respectively. There were four adenocarcinomas and six squamous
cell carcinomas in each group.
Micro RNA expression analysis
Out of 281 miRs, Figure 1 shows the number and distribution of
128 differentially expressed miRs significant across different
comparisons in the study (P,0.1 adjusted for false discovery rate,
FDR). The respective -up and down-regulated (21,1) miRs are
presented in Table S1. miR-182 was the only miR altered in all
three combinations; normal versus short DSS, normal versus long
DSS and short versus long DSS. A Principal component analysis
Table 1. Characteristics of 20 non-small cell lung cancer (NSCLC) patients and ten normal controls; NSCLC_01-10 with a short
disease-specific survival (DSS), NSCLC_11-20 with a long DSS and 10 normal controls (Norm_01-10).
Patient ID Histology DSS (months) Status Stage T N M Differentiation Age Sex
NSCLC_01 AC 6.5 LC Dead IIa 2a 1 0 Moderate 53 M
NSCLC_02 AC 7.0 LC Dead IIa 2a 1 0 Poor 73 M
NSCLC_03 SCC 7.3 LC Dead IIIa 1b 2 0 Poor 62 M
NSCLC_04 AC 7.4 LC Dead IIa 1b 1 0 Moderate 74 M
NSCLC_05 AC 7.6 LC Dead IIb 3 0 0 Poor 54 M
NSCLC_06 SCC 8.4 LC Dead IIb 3 0 0 Well 53 M
NSCLC_07 SCC 8.4 LC Dead IIb 3 0 0 Poor 74 M
NSCLC_08 SCC 9.3 LC Dead IIa 2a 1 0 Poor 74 M
NSCLC_09 SCC 9.6 LC Dead IIb 3 0 0 Poor 68 F
NSCLC_10 SCC 9.9 LC Dead IIb 3 0 0 Poor 70 F
NSCLC_11 SCC 147.8 Alive IIa 2a 1 0 Moderate 53 F
NSCLC_12 AC 74.1 Alive IIa 2b 0 0 Moderate 75 M
NSCLC_13 AC 60.5 Alive Ia 1b 0 0 Moderate 75 F
NSCLC_14 SCC 147.8 Alive IIa 2b 0 0 Moderate 60 M
NSCLC_15 SCC 163.8 Alive IIIa 3 1 0 Poor 68 M
NSCLC_16 AC 170.5 Alive IIa 2b 0 0 Moderate 47 M
NSCLC_17 SCC 158.7 Non-LC Dead Ib 2a 0 0 Moderate 69 M
NSCLC_18 AC 177.4 Alive IIb 3 0 0 Moderate 64 M
NSCLC_19 SCC 184.3 Non-LC Dead Ia 1b 0 0 Moderate 61 M
NSCLC_20 SCC 162.3 Alive Ia 1b 0 0 Moderate 53 M
*NORM_01 AC 6.5 LC Dead IIa 2a 1 0 Moderate 53 M
*NORM_02 AC 7.0 LC Dead IIa 2a 1 0 Poor 73 M
*NORM_03 SCC 8.4 LC Dead IIb 3 0 0 Well 53 M
*NORM_04 SCC 147.8 Alive IIa 2a 1 0 Moderate 53 F
*NORM_05 AC 74.1 Alive IIa 2b 0 0 Moderate 75 M
*NORM_06 AC 60.5 Alive Ia 1b 0 0 Moderate 75 F
*NORM_07 SCC 163.8 Alive IIIa 3 1 0 Poor 68 M
*NORM_08 AC 170.5 Alive IIa 2b 0 0 Moderate 47 M
*NORM_09 AC 177.4 Alive IIb 3 0 0 Moderate 64 M
*NORM_10 SCC 184.3 Non-LC Dead Ia 1b 0 0 Moderate 61 M
Abbreviations: SCC, squamous cell carcinoma; AC, adenocarcinoma; DSS; LC, lung cancer related; T, tumor; N, nodal status; M, metastasis.
*Samples from normal lung tissue sites in ten NSCLC patients (NSCLC_01, NSCLC_02, NSCLC_06, NSCLC_11, NSCLC_12, NSCLC_13, NSCLC_15, NSCLC_16, NSCLC_18 and
NSCLC_19) were included in the study (NORM_01 - NORM_10).
doi:10.1371/journal.pone.0029671.t001
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revealed that the main principle component of variation separates
normal samples from NSCLC samples. To highlight the difference
between the groups of NSCLC tumor samples a bridge partial
least squares (PLS) model was used to extract a subspace where the
group differences are more obvious than in PCA (Figure 2B).
Table 2 shows the ten miRs with highest fold change stratified into
the groups long survival versus normal control and short survival
versus normal control. Table 3 shows the miRs with highest fold
change in short versus long survival groups.
Pathway analysis
Table 4 shows results from the GSEA. The gene set connected
to 31 angiogenesis-related miRs revealed the highest gene set
nominal enrichment score (NES=21.17, nominal p-value 0.28,
FDR 0). Figure 3 shows the heat map representing 31miRs
connected to the angiogenic gene set.
PCR validation
Scatter plots comparing microarray hybridization and qPCR
data from 28 selected miRs are shown in Figure 4. The included
miRs, and data from all three combinations (both hybridization
and qPCR) are listed in Table S2. There were strong and
significant correlation between the hybridization and qPCR data:
Short versus normal r=0.81, P,0.001; long versus normal
r=0.85, P,0.001; short versus long r=0.85, P,0.001.
Correlation analysis between angiogenic markers and
miR-155
We have previously published on the prognostic impact of miR-
155 in our large (335 patients) NSCLC population [37]. In this
study we explored the correlation between miR-155 and several
well-known angiogenic markers. The same cut-off values as
previously published were used for FGF2 and miR-155 [33,37].
Figure S1 shows in situ hybridization (ISH) analysis of NSCLC
representing strong and weak intensities for tumor cell miR-155
expression as well as negative and positive controls. Table 5 shows
the correlation between angiogenic markers [vascular endothelial
growth factor - A (VEGF-A), platelet derived factor – B (PDGF-B),
HIF-1a and fibroblast growth factor 2 (FGF2)] and miR-155.
miR-155 correlated significantly with FGF2 in the total cohort
(r=0.17, P=0.002), though most prominent in the subgroup with
nodal metastasis (r=0.34, P,0.001). The crosstabs in Table 6 and
Table 7 show the correlation and distribution of high and low
expression of FGF2 and miR-155.
Discussion
To our knowledge, this is the first NSCLC miR expression
profiling study showing a gene set connected to angiogenesis-
related miRs with the highest impact in pathway analysis.
Consistent with previously published studies we observe significant
differences in miR profiles between normal and tumor tissue and
between samples from patients with a poor versus a favorable
DSS. Several of these significant altered miRs are associated with
angiogenesis and are interesting candidate markers for further
evaluation. By validating one of these markers, miR-155, in a
cohort of 335 NSCLC patients, we find this miR for the first time
to be significantly associated with the well-known angiogenic
marker FGF2.
The major weaknesses of the study in the search for novel
candidate markers are the relatively heterogeneous study popula-
tion and the low number of patients included in the analysis. Many
of the results presented herein are therefore only borderline
significant (or some only showing a trend) and further validation in
a larger NSCLC set, as done for miR-155, is a prerequisite for
firmer conclusions. This is especially the case when comparing
significant differences between tumor tissues (long versus short
survival) as there, in general, are larger differences between tumor
tissues and normal controls. The fold changes are in average
higher and the p-values stronger in Table 2 (tumor tissue versus
normal controls) compared with Table 3 (long versus short
survival). From a clinical point of view, at least when it comes to
miRs as potential prognostic or predictive markers, miRs with
altered expression between short versus long survival group are of
special interest. We have therefore explored the literature on four
angiogenesis related miRs from Table 3 (miR-106a, miR-155,
miR-182 and miR-424) and validated miR-155 in a large set of
NSCLC patients. In addition we wanted to highlight the potential
impact of miR-21, miR-126 and miR-210 from Table 2 as there
are convincing reports indicating these miRs to have potential
impact in angiogenesis. Besides, we have previously shown miR-
126 to have prognostic impact in our NSCLC cohort [38].
Strengthening our results are strong and significant correlations
between the microarray hybridization data and the same miRs
validated by qPCR. Further, the altered miR expressions in tumor
versus normal tissue are to a large degree consistent with
previously published NSCLC miR studies [15–17,20] and as
discussed in the following there are constantly new literature
added, supporting our candidate miRs to be involved in
angiogenesis.
Figure 1. Comparison of survival groups of NSCLC patients. The
Venn diagram shows the number of all differentially expressed miRNAs
across different comparisons: Tissue from NSCLC patients with short
survival versus tissue from NSCLC patients with long survival, tissue
from normal lung versus tissue from NSCLC patients with long survival
and tissue from normal lung versus tissue from NSCLC patients with
short survival. Out of 281 miRs evaluated, the number of differential
expressed miRs with FDR adjusted P,0.1 (total n=128) of each
comparison is indicated.
doi:10.1371/journal.pone.0029671.g001
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miR gene targets in NSCLC. The interpretation of such analyses is
not straight-forward as the results are highly dependent on which
target genes are linked to the miRs and which miRs are connected
to the different pathways. In addition miRs are often multifunc-
tional and the same miR may target diverse genes in different
pathways, and a gene may be targeted by several miRs. Although
not statistically significant, the GSEA ranged angiogenesis as the
most important pathway in our NSCLC samples. There are
several novel reports connecting specific miRs to angiogenesis
supporting our findings [23,24,39–42]. Besides, Raponi et al. have
shown that the angiogenesis-related fibroblast growth factor (FGF)
pathway had a significant gene enrichment in squamous NSCLC
[17].
In a comprehensive murine study, Olson et al. identified specific
miR expression signatures associated with steps in tumorigenesis
and different hallmarks of cancer, including angiogenesis [23].
Angiogenesis–inhibiting signature miRs were evaluated by qPCR
technique and defined as those miRs significantly altered in
normal versus sunitinib-treated primary tumors by .1.3 fold
change [23]. Sunitinib is a tyrosine kinase inhibitor targeting
vascular endothelial growth factor receptor (VEGFR), platelet-
derived growth factor (PDGFR) and c-Kit. In accordance with our
qPCR validation results, PCR data in general often show an
increased fold change compared with hybridization data. Many of
the angiogenesis–related miRs observed by Olson and coworkers
are also significantly altered in our material [23]. Among the most
interesting angiogenesis-related miRs significantly altered in both
studies we find miR-126, miR-155, and miR-21 and miR-424.
miR-126 has recently been reviewed as an important player in
angiogenesis [43] and Wang et al. showed in a murine model that
it enhances the proangiogenic actions of VEGF and FGF by
repressing the expression of Spred-1, an intracellular inhibitor of
angiogenic signaling [44]. miR-126 has also been located within
the epidermal growth factor-like domain 7 (EGFL7) gene. EGFL7
may have a major role in angiogenesis by promoting VEGF
signaling and vascular integrity [45]. Moreover, we have
previously reported that miR-126 expression is significantly
associated with VEGF-A in NSCLC [38]. Further, we observed
that the prognostic impact of miR-126 is related to histological
subtypes and nodal status. In addition the expression and roles of
miR-126 may be different in various malignancies [23].
miR-155 is one of the miRs most consistently involved in
neoplastic disease [46], but to our knowledge, not been related to
Figure 2. Principal component analysis (PCA) and partial least square analysis (PLS) on different NSCLC patient samples. (A) Two-
dimensional PCA of miRs, derived from 20 patients with NSCLC and 10 tissue samples from normal lung tissue, showing separation of the two sample
groups. (B) The plot depicts components 1 and 2 of PLS model which used survival time as a scoring criteria. The analysis clearly separates the tissue
sample groups for short and long survival NSCLC patients. All samples are colour coded according to group: Black: Normal patient samples; green:
Samples from patients with short survival; red: Samples from patients with long survival.
doi:10.1371/journal.pone.0029671.g002
Table 2. Ten each of the differentially expressed miRs that are up- or down-regulated the most ranged by fold change (long
survival versus normal control and short survival versus normal control).
Long survival versus normal Short survival versus normal
miR Fold change P-adjusted* miR Fold change P-adjusted*
Up- miR-205 8.75 0.0273 miR-1308 3.92 0.0117
regulated miR-21 3.68 0.0090 miR-21 3.63 0.0094
miR-1308 2.89 0.0532 miR-182 3.32 0.0008
miR-93 2.11 0.0443 miR-31 2.87 0.0362
miR-1274a 1.99 0.0675 miR-205 2.75 0.2917
miR-182 1.80 0.0939 miR-193b 2.31 0.0062
miR-708 1.75 0.0039 miR-1259 2.28 0.0008
miR-210 1.74 0.0070 miR-93 2.23 0.0337
miR-1259 1.64 0.0427 miR-106a 2.23 0.0933
miR-106b 1.62 0.1644 miR-183 2.20 0.0304
Down-regulated
rrregulatedregulated
miR-451 5.74 0.0427 miR-451 5.85 0.0397
regulated miR-126 4.53 0.0005 miR-126 4.09 0.0008
miR-30a 3.14 0.00006 miR-30a 2.81 0.0003
miR-30b 3.07 0.0124 miR-140-3p 2.68 0.0035
miR-30c 2.45 0.0035 miR-143 2.33 0.0787
miR-140-3p 2.45 0.0070 miR-126* 2.28 0.0035
miR-126* 2.41 0.0016 miR-145 2.22 0.0070
miR-145 2.28 0.0061 miR-30b 2.07 0.0958
let-7a 2.25 0.0480 miR-29c 2.01 0.0934
miR-125a-5p 2.19 0.00001 miR-30d 1.89 0.0200
*P-adjusted; corrected for false discovery rate (FDR).
doi:10.1371/journal.pone.0029671.t002
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been reported to be up-regulated in several human NSCLC
studies [15,17,20], and down-regulated in a murine model when
using the angiogenic inhibitor sunitinib [23]. In our array data,
miR-155 tended to be significantly altered between the short and
long survival groups (Table 3) and was significantly over-expressed
in tumor versus normal tissue in the qPCR validation set. We have
reported the prognostic impact of miR-155 to be associated with
histological subtypes and nodal status but did not link these results
to angiogenic markers [37]. Based on these new data we now
examined whether miR-155 correlated to well-known angiogenic/
hypoxic parameters as VEGF-A, PDGF-B, HIF-1a and FGF2.
Interestingly, we observed, for the first time, miR-155 to be
significantly associated with FGF2 with the highest impact in the
N+ NSCLC subgroup. Though FGF2 has several functions, it is
an important player in angiogenesis. In fact, miR-155 also tended
to correlate with VEGF-A in the N+ subgroup. miR-155 was one
of the first miRs to be associated with NSCLC development and
further studies will be important in order to explore its potential
angiogenic function.
In this study, miR-21 is significantly up-regulated in tumor
versus normal tissue (Table 2), supporting previous NSCLC
reports [15,17,20] and the observed down-regulation after anti-
angiogenic treatment [23]. miR-21 has also been found to be
highly expressed in endothelial cells [24]. In a recent study by Liu
et al., miR-21 was overexpressed by transfecting pre-miR-21 into
human prostate cancer cells and tumor angiogenesis was assayed
using chicken chorioallantoic membrane [47]. They found that
overexpression of miR-21 in DU145 cells increased the expression
of HIF-1a and VEGF, and induced tumor angiogenesis. They
conclude that miR-21 induces tumor angiogenesis through
targeting PTEN, leading to activation of the AKT and ERK1/2
signaling pathways, and thereby enhancing HIF-1a and VEGF
expression. The same pathways are described as important in
NSCLC development as well [48], and further studies to address
this relationship with miR-21 in lung cancer would be of interest.
The Olson study indicates miR-424 to be involved in
angiogenesis as this miR was down-regulated after sunitinib
treatment [23]. In addition, Ghosh et al. have studied this miR
and described that hypoxia-induced miR-424 expression in
human endothelial cells regulates HIF-a isoforms and promotes
angiogenesis [49]. They further suggest miR-424 to play an
important physiological role in post-ischemic angiogenesis. In
contrast, Nakshima et al. reported down-regulation of miR-424 to
contribute to the abnormal angiogenesis via MEK1 and cyclin E1
in senile hemangioma, demonstrating the potential tissue and stage
specific impact of the same miR [50]. In our study, miR-424 was
not altered when comparing tumor with normal tissue, but was
significantly up-regulated in tissue from patients with poor
prognosis compared to tissue from patients with a favorable
prognosis (Table 3). There is to our knowledge no published study
which has explored the prognostic impact of miR-424 in cancer.
However, as there is a significant miR-424 up-regulation in the
poor prognostic group it would be of interest to further evaluate
this marker in a large scale NSCLC study.
Another significant up-regulated marker in our material is miR-
210 (Table 2), which previously has been related to angiogenesis
[41,51,52]. miR-210 up-regulation is believed to be a crucial
element of endothelial cell response to hypoxia and therefore
potentially important in tumor angiogenesis. This miR has
recently been reviewed by Devlin et al. [51], concluding that
miR-210 is a robust target of hypoxia-inducible factor and that its
overexpression has been detected in a variety of cardiovascular
diseases and solid tumors. In NSCLC cell lines, miR-210 is
reported to mediate mitochondrial alterations associated with
modulation of HIF-1 activity [52]. However, much of the
functional and prognostic impact of miR-210 in NSCLC still
remains unresolved.
miR-182 is included in the angiogenesis pathway in the GSEA,
partly because fibroblast growth factor receptor substrate 2 (FRS2)
is one of its target genes. FRS2 is a major regulator of the
fibroblast growth factor pathway that we and others have shown to
be important in NSCLC progression, potentially by stimulating
angiogenesis [33,53]. Interestingly, miR-182 was the only miR
significantly altered in all three combinations as shown in the
Venn diagram (Figure 1). Its up-regulation in tumor (both poor
and favorable prognostic group, Table 2) when compared to
normal tissue, is consistent with the previous study by Raponi et al.
[17]. Moreover, miR-182 is significantly up-regulated in short
DSS versus long DSS patients (Table 3). However, Barchack et al.
observed higher miR-182 expression in primary tumors than in
the metastatic lung tumors, indicating that miR-182 expression
may reach a peak in early stage NSCLC.
We observe the same trend for miR-106a, which has been
shown to be up-regulated during hypoxia in breast and colon
cancer cell lines [40]. As previously reported, miR-106a was up-
regulated in NSCLC [16,17,20]. We also observe its expression to
be significantly augmented in tumors versus normal controls
(Table 2). As for miR-182, miR-106a was further increased in
tissue from patients with a short survival rather than long survival
(Table 3).
As expected, many miRs known to be associated with
angiogenesis were not significantly altered in our study. Cluster
Table 3. Ten each of the differentially expressed miRs that
are up- or down-regulated the most ranged by fold change
(short survival versus long survival).
Short survival versus long survival
miR Fold change P-adjusted*
Up- miR-31 2.00 0.161
regulated miR-182 1.85 0.084
miR-106a 1.73 0.245
miR-183 1.72 0.094
let-7a 1.68 0.194
miR-151-5p 1.64 0.093
miR-138-1* 1.61 0.073
miR-98 1.56 0.089
miR-424 1.53 0.044
miR-193b 1.50 0.178
Down- miR-205 3.16 0.232
regulated miR-142-3p 1.96 0.084
miR-557 1.65 0.084
miR-720 1.52 0.078
miR-378 1.44 0.070
miR-708 1.41 0.075
miR-29c 1.39 0.076
miR-552 1.35 0.084
miR-27a* 1.32 0.035
miR-155 1.31 0.095
*P-adjusted; corrected for false discovery rate (FDR).
doi:10.1371/journal.pone.0029671.t003
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GS Size Pathway NES NOM p-value FDR
P00005 31 Angiogenesis 21.17 0.28 0
P00027 17 Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha
mediated pathway
21.16 0.28 0
P00004 42 Alzheimer disease-presenilin pathway 21.12 0.33 0.35
P00047 37 PDGF signaling pathway 21.12 0.32 0.26
P00029 37 Huntington disease 21.08 0.41 0.35
P00059 21 p53 pathway 21.06 0.43 0.31
P00006 28 Apoptosis signaling pathway 21.06 0.50 0.28
P00048 18 PI3 kinase pathway 21.04 0.46 0.27
P00031 45 Inflammation mediated by chemokine and cytokine signaling pathway 21.03 0.49 0.26
P00019 19 Endothelin signaling pathway 21.00 0.50 0.33
P00036 35 Interleukin signaling pathway 20.98 0.51 0.37
P00057 62 Wnt signaling pathway 20.98 0.54 0.34
P00052 44 TGF-beta signaling pathway 20.89 0.66 0.56
P00034 43 Integrin signalling pathway 20.89 0.68 0.53
P00012 40 Cadherin signaling pathway 20.87 0.66 0.55
P00046 22 Oxidative stress response 20.86 0.67 0.55
P00026 33 Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha
mediated pathway
20.85 0.68 0.57
P04398 28 p53 pathway feedback loops 2 20.83 0.74 0.58
P00016 23 Cytoskeletal regulation by Rho GTPase 20.81 0.71 0.59
P00060 44 Ubiquitin proteasome pathway 20.73 0.81 0.81
P00007 16 Axon guidance mediated by semaphorins 20.67 0.87 0.90
GS, gene set; Size, numbers of miRs included; NES, nominal enrichment score; NOM p-value, nominal p-value; FDR, false discovery rate.
doi:10.1371/journal.pone.0029671.t004
Figure 3. Heat map showing expression of 31 microRNAs (miRs) included in angiogenesis pathway gene set. The difference in miR
expression between tumor samples from NSCLC patients with long (L) and short (S) survival is shown. miR expression values are shown in a spectrum
where down-regulated is blue and up-regulated is red.
doi:10.1371/journal.pone.0029671.g003
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miR-20a and miR92-1), let-7, let-7f, miR-27b, miR-15b, miR-16,
miR-92a, miR-99a, miR-130a, miR-214, miR-221, miR-222 and
miR-296 as well as some of the miRs presented in the heat map
(Figure 3), were not significantly altered or they exhibited only
minor fold changes [24,39,41,42]. This lack of significant
alterations may be due to false negative results as there are few
patients in each group. Furthermore, as many miRs appear to be
tissue and stage specific, some of these miRs may alternatively
exert an impact limited to subgroups of resected NSCLC or may
be important in other malignancies.
Angiogenic inhibitors in combination with chemotherapy are
established as NSCLC treatment, but a further knowledge on
biology, effectors mechanisms and prognostic and predictive
markers are warranted. miRs are stable and potentially measur-
able in both tissue and serum. Several miRs are linked to
angiogenesis and this study supports the assumption that a number
of angiogenesis-related miRs are potentially important in NSCLC
progression. We propose miR-21, miR-106a, miR-126, miR-155,
miR-182, miR-210 and miR-424 to be among the most interesting
candidates. Since miRs often are stage and tissue specific, large
scale studies are warranted to further explore their prognostic and
Figure 4. Scatter plot comparing microarray hybridization (all ten samples in each group) and qPCR data (five selected samples
from each group: NSCLC_03, NSCLC_05, NSCLC_08, NSCLC_10, NSCLC_15, NSCLC_16, NSCLC_17, NSCLC_18, NSCLC_19,
NSCLC_20, NORM_03, NORM_04, NORM_08, NORM_09 and NORM_10) and 28 miRs according to Table S2. Comparison between
microarray hybridization (dLMR, difference in average expression levels between sample groups, log2 scale) and qPCR (ddCP, difference in average
expression levels between sample groups, log2 scale) data, correlation coefficient=r (Pearson): (A) low versus normal r=0.81, P,0.001; (B) high
versus normal r=0.85, P,0.001; (C) high versus low r=0.85, P,0.001. In red; miR-150.
doi:10.1371/journal.pone.0029671.g004
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genes and different functions. Therefore functional studies are
highly needed to gain better insight into their biological functions.
Materials and Methods
Ethics statement
The study is approved by The National Data Inspection Board,
The Regional Committee for Research Ethics and Biobank Board
Collection of Tissue. Information and subsequent written consent
from patients or next of kin was considered, but as this was a
retrospective study with more than half of patients deceased, some
more than ten years ago, The Regional Committee for Research
Ethics specifically waived the need for consent.
Patients and tissue samples
From a previously well-described large NSCLC cohort [30],
twenty formalin-fixed and paraffin-embedded (FFPE) tumor tissue
samples were obtained from patients diagnosed with stage I-IIIA
at the University Hospital of Northern Norway (UNN) and
Nordland Central Hospital (NLCH). These were ten patients with
a short disease-specific survival (DSS) (NSCLC_01 - NSCLC_10),
and ten patients with long DSS (NSCLC_11 - NSCLC_20). In
addition, samples from normal lung tissue sites in ten NSCLC
patients (NSCLC_01, NSCLC_02, NSCLC_06, NSCLC_11,
NSCLC_12, NSCLC_13, NSCLC_15, NSCLC_16, NSCLC_18
and NSCLC_19) were included in the study (NORM_01 -
NORM_10). Four sample cores, each 0.6 mm in diameter, from
viable tumor areas from each tumor and normal specimen were
taken and pooled prior to RNA isolation in order to obtain a
representative sample of each patient. Long and short DSS groups
were stratified in order to get equal distribution of gender and
histology. The tumor specimens were stored at the Departments of
Pathology at UNN and NLCH, staged according to The
International Union Against Cancer (UICC) TNM classification,
and histologically subtyped according to the World Health
Organization guidelines [54,55]. All patient material was reviewed
by two independent and trained pathologists (SAS and KAS).
None of the patients received chemo- or radiotherapy prior to
surgery. Complete patient data was obtained from medical
records, including demographic, clinical, treatment and outcome
data.
RNA isolation
RNA was isolated from the collected core samples by using the
Recover All
TM Total Nucleic Acid Isolation Kit for FFPE Tissues
(Ambion, Austin, TX), according to the manufacturer’s instruc-
tions, with some minor adjustments. Xylene treatment was
increased from 3 min to 8 min, and protease treatment was
increased from 3 hrs to approximately 20 hrs. RNA quality and
quantity was assessed by using the NanoDrop 1000 spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE) and further
verified by an Agilent 2100 Bioanalyzer profile.
Microarray procedures
Total RNA (700 ng) from sample and reference was labelled
with Hy3
TM and Hy5
TM fluorescent label using the miRCURY
Tm
LNA Array power labelling kit (Exiqon, Vedbaek, Denmark)
following the procedure described by the manufacturer. The
Hy3
TM-labeled samples and a Hy5
TM-labelled reference RNA
sample (containing an equal aliquot of all RNA species included in
this study) were mixed pair-wise and hybridized to the miCUR-
Y
Tm LNA Array version 5
th generation (Exiqon, Denmark), which
contains capture probes targeting all human miRNAs registered in
the miRBASE version 14.0 at the Sanger Institute. The
hybridization was performed according to the miRCURY
TM
LNA array manual using a Tecan HS4800 hybridization station
(Tecan, Austria). After hybridization the microarray slides were
scanned and stored in an ozone free environment (ozone level
below 2.0 ppb) in order to prevent potential bleaching of the
fluorescent dyes. The miCURY
TM LNA Array microarray slides
were scanned using the Agilent G2565BA Microarray Scanner
System (Agilent technologies Inc., USA) and the image analysis
was carried out using the ImaGene 8.0 software (BioDiscovery
Inc., USA). The quantified signals were background corrected
with offset value 10 and normalized using the global Lowess
(Locally Weighted Scatterplot Smoothing) regression algorithm
[56].
Database submission of microarray data
The microarray data were prepared according to minimum
information about a microarray experiment (MIAME) recom-
Table 5. Correlation analyses between angiogenic markers
and miR-155 expression in NSCLC patients.
miR-155
Total cohort (n=335) N0 (n=232) N+ (n=103)
VEGF-A r=0.09, P=0.11 r=0.05, P=0.50 r=0.18, P=0.07
PDGF-B r=0.04, P=0.49 r=0.06, P=0.37 r=0.01, P=0.96
HIF-1a r=0.02, P=0.68 r=0.02, P=0.75 r=20.1, P=0.27
FGF2 r=0.17, P=0.002 r=0.06, P=0.35 r=0.34, P,0.001
Abbreviations: VEGF-A, vascular endothelial growth factor-A; PDGF-B, platelet
derived factor -B; HIF-1a, hypoxia inducible factor 1a; FGF2, fibroblast growth
factor 2; N0, lymph node negative patients; N+, lymph node positive patients.
doi:10.1371/journal.pone.0029671.t005
Table 6. Crosstab showing the correlation between miR-155
and FGF2 in the total cohort.
miR-155
Low expression High expression Total
FGF2 Low expression 156 137 293
High expression 62 1 27
Total 162 158 320
Spearman correlation, r=0.17, P=0.002.
doi:10.1371/journal.pone.0029671.t006
Table 7. Crosstab showing the correlation between miR-155
and FGF2 in patients with lymph node metastasis (N+).
miR-155
Low expression High expression Total
FGF2 Low expression 48 37 85
High expression 11 3 14
Total 49 50 99
Spearman correlation, r=0.34, P,0.001.
doi:10.1371/journal.pone.0029671.t007
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www.ncbi.nlm.nih.gov/geo/). The GEO accession number for the
platform is GSE27705 and the study may be viewed at: http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27705.
Quantification of mature miRNAs by real-time qPCR
One or several of the following criteria were used when selecting
miRs for PCR validation; significant P-value, high fold change
and/or angiogenesis-related miRs. Five samples from each group
with sufficient tumor miR remaining after the array analysis were
used in the PCR validation. Out of the 41 tested miRs, 28 miRs
were detected in 7 or more samples and analysed. The stability of
the miRNAs detected in all samples was tested by Exicon using the
Normfinder software. miR-423-5p was one of the recommended
reference miRNAs together with miR-150, miR-423-5p and miR-
300. miR-300 was excluded due to very low levels detected.
Further Normfinder found large variation in miR- 150, however
miR-423-5p was found to be the most stable miRNA in the data
set and consequently used as reference. All real-time qPCR
experiments were performed by Exiqon, Vedbaek, Denmark.
10 ng RNA was reverse transcribed in 10 ml reactions using the
miRCURY LNA
TM Universal RT miR PCR, Polyadenylation
and cDNA synthesis kit (Exiqon); each sample was processed in
triplicates. cDNA was diluted 1006 and 4 ul was used in 10 ul
PCR reactions according to the protocol for miRCURY LNA
TM
Universal RT miR PCR; each miR was assayed once by qPCR in
triplicate cDNA. The amplification was performed in a Light-
CyclerH 480 Real-Time PCR System (Roche) in 384 well plates.
LinRegPCR (version 11.5) software was used to determine the
qPCR amplification efficiency. The average amplification effi-
ciency was used to correct the Raw Cp values.
Pathway analysis
The impacts of the different pathways were evaluated by Gene
Set Enrichment Analysis (GSEA) derived from Protein ANalysis
THrough Evolutionary Relationship (PANTHER). The PAN-
THER classification system is a unique resource that classifies
genes by their functions, using published scientific experimental
evidence and evolutionary relationships to predict function even in
the absence of direct experimental evidence. The gene set was
taken from the MirDB (http://www.mirdb.org) (http://rnajour-
nal.cshlp.org/content/14/6/1012.full) database who has compiled
gene lists from pathways curated in the PANTHER database.
A full list is available at http://mirdb.org/cgi-bin/pathway.cgi.
miRNA annotation is based on miRBase version 13 (http://www.
mirbase.org/). GSEA analysis was carried out using the R statistical
language (www.r-project.org) and the GSEA package for R
available at http://www.broadinstitute.org/gsea/downloads.jsp.
Data analysis and statistical analysis
The data were analyzed using Linear Models and Empirical
Bayes Methods for Assessing Differential Expression in Microarray
experiments (LIMMA) [58], and significance was determined at
the 0.1 level corrected for false discovery rate (FDR) using the
method of Benjamini & Hochberg [59]. Principal component
analysis (PCA) and Partial least squares (PLS) were carried out on
the data in order to visualize the data structure and look for
potential outlier samples [60].
The enrichment score (ES) reflects the degree to which a gene
set is overrepresented at the top or bottom of a ranked list of genes.
Normalized enrichment scores (NES) are used to compare analysis
results across gene sets. GSEA accounts for differences in gene set
size and in correlations between gene sets and the expression
dataset [61]. The false discovery rate (FDR) is the estimated
probability that a gene set with a given NES represents a false
positive finding. The nominal p- value estimates the statistical
significance of the enrichment score for a single gene set.
Pearson’s correlation coefficient, r, was used to describe the
association between array data and results from qPCR. Pearson
Chi-Square and Fisher Exact Test were used to correlate
angiogenic markers with miR-155.
Supporting Information
Figure S1 In situ hybridization (ISH) analysis of NSCLC
representing strong and weak intensities for tumor cell
miR-155 expression. Negative (scramble-miR) and positive
(U6) controls from the same tissue area are shown. Strong miR-
155 staining (A) with corresponding negative (C) and positive (E)
controls to the left. Weak miR-155 staining (B) with corresponding
negative (D) and positive (F) controls to the right. ISH positive
signals (miR-155 and U6) stain blue, while nuclei stain red.
(TIF)
Table S1 The 128 significant -up and down-regulated
(21, 1) miRs are presented with FDR adjusted p-values
and respective fold changes (log2 scale).
(XLS)
Table S2 Comparison between the array and the qPCR
data in validation set. The differences in average expression
levels between the sample groups in the array study are shown in
columns 2–4 (dLMR values=log2 scale). The differences in
average expression levels between the sample groups in the qPCR
study are shown in columns 5–7 (ddCp values=log2 scale).
Positive numbers .1 are shown in red (=fold change .2),
negative numbers ,21 (=fold change .22).
(DOC)
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